Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.

Expert opinion on pharmacotherapy - 1 Jan 2015

Zia Yasaman, Chen Lawrence, Daud Adil

Abstract excerpt

INTRODUCTION: Combination therapy with BRAF and MEK inhibitors is a recommended treatment strategy for metastatic melanoma patients with BRAF(V600) mutations. This treatment provides significant response rates and little added toxicity, with relatively improved survival outcomes compared to RAF/MEK inhibitor monotherapy and chemotherapy. AREAS COVERED: This review covers the pharmacology, efficacy, and toxicity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Imidazoles
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 2

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Skin Neoplasms

Source

Identifiers

PMID: 26331795
DOI: 10.1517/14656566.2015.1085509

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.PMID 26331795Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Semantic proximity Read ↗

Improved overall survival in melanoma with combined dabrafenib and trametinib.Semantic proximity Read ↗

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Semantic proximity Read ↗

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Semantic proximity Read ↗

Trametinib in the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.